IMCR vs LLY
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
IMCR exhibits severe fundamental weakness, highlighted by a critical Piotroski F-Score of 1/9, indicating poor financial health and operational deterioration. While the company maintains an impressive gross margin of 96.53% and positive revenue growth of 24.3%, these are offset by a catastrophic year-over-year EPS decline of 452.9% and a bearish insider sentiment. There is a stark disconnect between the aggressive analyst target price of $63.86 and the actual deterministic data, which suggests a high-risk profile characterized by consistent earnings misses and insider liquidation.
LLY shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
Compare Another Pair
Related Comparisons
IMCR vs LLY: Head-to-Head Comparison
This page compares Immunocore Holdings plc (IMCR) and Eli Lilly and Company (LLY) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.